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Abstract
Background: We present here the case of a patient with pulmonary arterial hypertension and NYHA Class II
symptoms who transitioned from PDE-5i therapy to riociguat. No protocol currently exists for transitioning between
these PAH medications.
Case presentation: A 59-year old male with a history of anorexigen use initially presented in 2008 and was felt to
have non-operable small vessel disease. His care was transitioned to our center after insurance would not cover
high-dose sildenafil in addition to ERA therapy.
Conclusion: This case demonstrates a safe and successful transition from higher dose PDE-5is to riociguat with no
interruption in therapy.
Keywords: Pulmonary arterial hypertension, sGC stimulators, Cyclic guanosine monophosphate, Chronic
thromboembolic pulmonary hypertension
Background
Pulmonary arterial hypertension (PAH) is a rare, life-
threatening disease defined by chronically elevated pres-
sure in the pulmonary arteries [1]. The etiology of PAH
can be idiopathic, familial, or associated with underlying
disease, such as connective tissue diseases, certain auto-
immune congenital cardiac conditions, and human im-
munodeficiency virus. PAH is also caused by exposure
to drugs or toxins, namely anorectic agents and other
stimulants [2].
The pathophysiology of PAH is multifactorial and in-
cludes increased expression of the vasoconstrictors
endothelin-1 and thromboxane, along with reduced
vasodilator activity of the prostacyclin and nitric oxide
(NO) pathways. The resultant pulmonary vascular
remodeling produces thickened vessel walls and narrow-
ing of arterial lumens. As the disease progresses, compen-
satory stress on the right ventricle weakens the cardiac
muscle, ultimately resulting in right heart failure [3].
Clinically, PAH is defined as a mean pulmonary arter-
ial pressure (mPAP) of ≥25 mmHg at rest, pulmonary
capillary wedge pressure (PCWP) of ≤15 mmHg, and
pulmonary vascular resistance (PVR) >3 Wood Units
(240 dyn · s/cm5) [1]. Patients typically present with dys-
pnea on exertion (DOE), fatigue, dizziness/syncope, an-
gina, and edema. If untreated or inadequately treated,
patients generally have a life expectancy of less than
5 years [4].
Primary treatment goals in PAH are to improve symp-
toms, stabilize or improve New York Heart Association
functional class (NYHA FC), and prevent disease pro-
gression. Therapeutic agents act on one of the vasoactive
pathways implicated in PAH. Endothelin-receptor antag-
onists (ERAs), phosphodiesterase-5 inhibitors (PDE-5is),
and prostacyclins are mainstays of therapy [5]. Initial
therapy choice is dictated largely by WHO FC. The
standard treatment approach was, until recently, sequen-
tial add-on therapy whereby patients start on one ther-
apy and additional therapies are added until treatment
goals are achieved. However, recent data have shown up-
front combination therapy to be of benefit and recent
guidelines updates from the European Respiratory Soci-
ety (ERS) and European Society of Cardiology (ESC)
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provide recommendations for both initial drug combin-
ation therapy and sequential drug add-on therapy. Com-
bination therapy is an attractive therapeutic option as it
may target all three signaling pathways implicated in the
pathogenesis of PAH [5–7].
There are four different classes of compounds ap-
proved for PAH, two stimulators (prostanoids and
soluble guanylate cyclase [sGC] stimulators) and two in-
hibitors (ERAs and PDE5 inhibitors). Each of these clas-
ses has a distinct molecular target. Riociguat is the first
member of a novel class of therapeutics called sGC stim-
ulators [8]. Riociguat has a dual mode of action. It sensi-
tizes sGC to endogenous NO by stabilizing NO–sGC
binding. Riociguat also directly stimulates sGC via a dif-
ferent binding site, independently of NO. Riociguat re-
stores the NO–sGC–cyclic guanosine monophosphate
(cGMP) pathway and leads to increased generation of
cGMP. In PAH clinical trials, riociguat has been shown
to significantly improve exercise capacity, as well as im-
prove a range of secondary endpoints, including pul-
monary hemodynamics, WHO FC, and time to clinical
worsening [9].
Case presentation
The patient is a 59-year-old man first seen for pulmon-
ary testing and evaluation at the University of California,
San Diego (UCSD) Medical Center in 2008. He was re-
ferred to our center by his pulmonologist, who sus-
pected PAH based on symptoms of worsening DOE and
the patient’s self-reported use of anorexigens in the
1990s.
As part of the initial diagnostic work up in 2008, the
patient underwent right heart catheterization (RHC),
which indicated an mPAP of 35 mmHg with a PCWP of
6 mmHg; cardiac output (CO) was 6.27 L/min, cardiac
index (CI) was 2.8 L/min/m2 and PVR was 4.9 Wood
Units (388 dyn · s/cm5). Vasodilator testing was per-
formed with inhaled nitric oxide and the patient was not
vasoreactive.
A ventilation-perfusion (V/Q) scan demonstrated seg-
mental perfusion defects of small to moderate size in
both lungs. A pulmonary angiogram revealed narrowing
of all pulmonary vessels and distal pruning. The angio-
gram findings were consistent with a diagnosis of PAH
and no findings supporting a diagnosis of chronic
thromboembolic pulmonary hypertension (CTEPH)
were noted.
At the time of initial diagnosis the patient was NYHA
FC III and the etiology of his disease was attributed to a
prior history of anorexigen use. His referring pulmonolo-
gist initiated first-line therapy with bosentan 125 mg PO
BID followed by addition of sildenafil 40 mg PO TID.
In 2011, 3 years after starting first-line therapy, the
patient transitioned his care to UCSD. On ECHO,
estimated peak PAP had decreased to 27 mmHg. RHC
parameters had also improved from baseline evaluation:
mPAP was reduced to 22 mmHg, PCWP was similar to
initial findings at 5 mmHg, CO had increased to 6.37 L/
min, CI was now 2.94 L/min/m [2], and PVR was 3.1
Wood units.
Clinically, the patient was now NYHA FC II and given
his positive response to treatment, we made the decision
to maintain him on his current PAH regimen of an ERA
and PDE-5i. In February of 2014, the patient was seen as
part of his routine care at our pulmonary hypertension
center with stable NYHA FC II symptoms and a 6MWD
of 547 m. Due to a change in insurance coverage the pa-
tient was unable to obtain sildenfail 40 mg PO TID and
a decision was made to transition him to riociguat.
No protocol currently exists for transitioning patients
from a PDE-5i to riociguat. We performed our transition
without a washout. The patient took his last dose of sil-
denafil in the evening and the following morning started
riociguat 1 mg TID and titrated up by 0.5 mg every
2 weeks to the maximum therapeutic dosage of 2.5 mg
TID. The patient remained on bosentan 125 mg BID.
Both the transition to riociguat and the titration to max-
imum therapeutic dosage were well tolerated. The pa-
tient did not report any adverse events during switch or
maintenance, with the exception of mild heartburn that
was successfully managed with an over-the-counter H2
blocker.
An ECHO was performed 3 months after the patient
began therapy with riociguat and no significant changes
in hemodynamic parameters were noted from the previ-
ous study in 2011, when the patient was being treated
with a PDE-5i.
Subjectively, the patient reported an improvement in
his PAH symptoms on riociguat, especially in the area of
exercise tolerance. He stated that while on riociguat he
experienced increased energy and less breathlessness,
even while performing more strenuous exercise. An
amateur cyclist, the patient reports being able to ride his
bicycle longer and faster—an important personal goal
for him. Repeat 6MWD improved to 606 m. As the pa-
tient has remained stable with a subjective improvement
in symptoms and an improved 6MWD, he will continue
on riociguat 2.5 mg TID. He will undergo further assess-
ments at our center, but we have found both his safe
switch to riociguat and his initial therapeutic response to
be very encouraging.
Discussion
Recent clinical guidelines have included riociguat as ini-
tial therapy with grade I A/B recommendation for
patients with WHO FC II-III PAH [5]. Consensus based
guidelines from the American College of Chest Physicians
recommended riociguat as monotherapy for treatment-
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naïve WHO FC II-III patients and as add-on therapy in
WHO FC III-IV patients currently on stable doses of
ERAs or inhaled prostanoids [10]. The recently updated
ESC/ERS guidelines recommend riociguat as monother-
apy in WHO FC II-III patients (Grade IB) and as sequen-
tial drug combination therapy with bosentan in WHO FC
II-III patients (Grade IB) [7].
The phase III PATENT-1 trial of riociguat allowed PAH
patients on stable background ERA therapy who remained
symptomatic to receive individualized doses of riociguat
up to a maximum of 2.5 mg TID [11]. Results showed a
mean placebo-corrected change in in 6MWD from base-
line to last visit of 36 m. Further, the mean change in PVR
was −174 ± 202 dyn∙s∙cm−5 for riociguat versus −46 ±
266 dyn∙s∙cm−5 for placebo. By last visit, 26 % of riociguat
patients had improved one WHO-FC (71 % maintained
FC, while 4 % worsened 1 FC) compared with 13 % of pla-
cebo patients (76 % maintained FC, and 9 % and 2 %
worsened 1 and 2 FC, respectively) [11].
Administration of riociguat is contraindicated in pa-
tients currently receiving PDE-5i’s due to the risk of
hypotension [12]. Until recently, treatment paradigms
were sequential and additive, with PDE-5i’s traditionally
first-line add-on therapy, and ongoing studies are inves-
tigating the efficacy of riociguat combination therapy in
patients with insufficient response to PDE-5i’s. The RES-
PITE trial is an open-label, single-arm, uncontrolled
phase 3b study investigating whether patients who do
not have an adequate response to therapy with PDE-5i’s
may have insufficient synthesis of cyclic guanosine
monophosphate (cGMP), and as such may respond to
sGC stimulators [13]. PAH patients with an insufficient
response to stable doses of sildenafil or tadalafil for at
least 90 days will be switched to riociguat for 24 weeks.
Patients pretreated with a stable dose of sildenafil for
≥90 days will be switched to riociguat after a 24-h wash-
out and those pretreated with a stable dose of tadalafil
for ≥90 days will be switched to riociguat after a 72-
hourwashout. Riociguat will be individually dose-
adjusted in 0.5-mg increments during an 8-week titra-
tion phase to a maximum of 2.5 mg TID. A 16-week
maintenance phase will assess change from baseline in
6-min walk distance at 24 weeks as well as changes in
cardiac index, NT-proBNP, WHO FC, quality of life, and
the proportion of patients with clinical worsening. All
endpoints in the study are exploratory [13]. Results from
the phase 3b RESPITE study will determine if PAH pa-
tients who have an insufficient response to PDE-5i ther-
apy are likely to respond to treatment with an sGC
stimulator. The sGC stimulator riociguat is the first drug
in its class to be approved, and as it does not require the
presence of NO to stimulate sGC, riociguat may provide
benefits for patients who do not respond to PDE-5i due
to NO deficiency [14].
Conclusion
PAH is a life-threatening disease that requires vigilance
in therapeutic management to ensure that patients
remain stable for as long as possible. Treatment of PAH
is complicated not only by the multifactorial nature of
the disease but also by larger issues around medication
access. As new PAH agents are developed, clinicians
must decide how to integrate them into the treatment
algorithm. In the absence of formal guidelines for
switching stable patients to the novel PAH agent rioci-
guat, this case offers evidence of the potential for a safe
and clinically beneficial transition from a first-line PDE-
5i. In our patient the transition from PDE-5i to riociguat
was performed without washout. The safety of this ap-
proach with the longer acting PDE-5i, tadalafil, is un-
known. Similarly, transition without washout should be
approached cautiously in patients with low baseline sys-
temic blood pressure.
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